glp-1 for alcohol use disorder Emerging pharmacological targets GLP‐1 Receptor Agonists for Treating

As of July 1, 2024, there are 105 Ozempic, Wegovy, and Rybelsus gastroparesis cases pending in the Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation

Furthermore, the Outsourcing Facilities Association has sued the FDA, claiming the removal of semaglutide from the shortage list is arbitrary and capricious because there are still risks of supply shortages

[00:10:18] Emily Field: A very commonly suggested rate is about 0.5 to 1% of body weight lost per week

Stopping abruptly can lead to several challenges: 1

Regularly check in with WW clinicians to adjust the persons goals, plans, and medication

If cost, side effects, supply issues, limited results, or the thought of lifelong medication has you frustrated, weight loss surgery may offer a more durable path forward